The present invention relates to methods for prognosis and monitoring of a cancer, preferably bladder cancer, by measuring the proportion of CD8.sup.+ T Lymphocytes expressing ILT-2 and the plasma level of soluble HLA-G. The invention also relates to anti HLA-G antibodies for use for treating a cancer in which tumor cells express HLA-G, preferably bladder cancer.

Embodiments access an image of a region of interest (ROI) demonstrating cancerous pathology; extract radiomic features from the ROI; define a radiomic feature expression scene based on the ROI and radiomic features; generate a cluster map by superpixel clustering the expression scene; generate an expression map by repartitioning the cluster map into expression levels; compute a textural and spatial phenotypes for the expression map based on the expression levels; construct a radiomic spatial textural (RADISTAT) descriptor by concatenating the textural and spatial phenotypes; provide the RADISTAT descriptor to a machine learning classifier; receive, from the machine learning classifier, a first probability that the ROI is a responder or non-responder, or a second probability that the ROI will experience long-term survival or short-term survival, based, at least in part, on the RADISTAT descriptor; and generate a classification of the ROI as a responder or non-responder, or long-term survivor or short-term survivor.

The invention relates to assays, devices and kits for accurate determination of neutralizing antibodies levels in samples of a subject suffering from an immune-mediated disorder, treated with biological drugs, and for predicting responsiveness to the drug in these patients.

Method of selecting treatment for a subject diagnosed with cancer comprises contacting antibody that binds specifically to thymidine kinase 1 (TK1) protein with a first body fluid sample before completing cancer treatment; determining a first amount of antibody binding to TK1 protein in the first sample; correlating the first amount to a first concentration of TK1 protein using a standard curve correlating an amount of antibody binding to recombinant human TK1 (rhTK1) and a concentration of rhTK1; contacting the antibody with a second body fluid sample within one to six months after the cancer treatment; determining a second amount of antibody binding to TK1 protein in the second sample; correlating the second amount to a second concentration using the curve; identifying the patient as having a high risk of future cancer relapse if the second concentration is the first concentration; and selecting an adjuvant treatment based on the identification.

Provided herein are methods for identifying a subject as a responder or non-responder to immune checkpoint blockade by detecting a B cell signature. Further provided herein are methods for treating cancer by administering immune checkpoint blockade therapy to a subject identified to have a B cell signature.

The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.

The present disclosure relates to a method for predicting a recurrence and a progression of an urothelial cancer patient after a treatment including steps as follows. A urine sample is obtained from a subject. The urine sample is performing a serially centrifugation step to obtain a third precipitate. The third precipitate is resuspended with an extraction solvent to obtain a third mixture, and the third mixture is centrifuged to obtain a fourth supernatant. The fourth supernatant is analyzed by a mass spectrometry to detect whether there is a particular peptide therein.

The present invention relates to methods and biomarkers (e.g., protein biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer, providing a prognosis to colorectal cancer patients, and in companion diagnostics.

The present invention provides methods of detecting breast cancer or breast cancer cells comprising: (a) obtaining a liquid sample from a subject which sample comprises cells, microvesicles and/or exosomes; and (b) determining the presence of soluble or cell surface associated Cyr61 in the sample; wherein the liquid sample is selected from blood, and/or bone marrow aspirate and wherein the determination of the presence of Cyr61 comprises detection via ELISA.

The p21 biomarker is utilized in the evaluation of whether a patient is suffering from kidney injury or failure, and can be used in methods of treating kidney injury or failure by determining the appropriateness of one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.